Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients

Sir, It is with great interest that we read the Saudi Association for the Study of Liver diseases and Transplantation (SASLT) position statement [1] and guidelines [2] on direct-acting antiviral agents (DAAs) for the treatment of hepatitis C virus (HCV) infection. All patients with decompensated cir...

Full description

Saved in:
Bibliographic Details
Published in:Saudi journal of gastroenterology 2017-07, Vol.23 (4), p.263-264
Main Authors: Al-Busafi, Said A, Omar, Heba
Format: Article
Language:English
Subjects:
Antiviral Agents
Complications and side effects
Disease
Dosage and administration
Drug therapy
Health aspects
Health care expenditures
Hepacivirus
Hepatitis
Hepatitis C
Humans
Infections
Interferon
Letter to Editor
Liver
Medicine
Patients
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sir, It is with great interest that we read the Saudi Association for the Study of Liver diseases and Transplantation (SASLT) position statement [1] and guidelines [2] on direct-acting antiviral agents (DAAs) for the treatment of hepatitis C virus (HCV) infection. All patients with decompensated cirrhosis were delisted from transplantation. [...]healthcare leaders and policy makers at the national and international level should adopt strategies to ensure that these DAAs are made available and are accessible and affordable for all in need. SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection.
ISSN:1319-3767
1998-4049
DOI:10.4103/sjg.SJG_136_17